SecBot SecBot

ANIK drug pipeline

Anika Therapeutics, Inc. · 4 rated drugs
$12.92
−3.6% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.3%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
4
4 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePre-NDA (US drug application path; not a standard clinical phase)
Time to marketUnknown, and likely 2027 at the earliest: the NDA had not been confirmed as filed as of mid-2026, and a US approval decision would typically come roughly 10 months after a completed, accepted submission.

CINGAL Updated Aug 1

What to watch

Watch Anika's Q3 2026 earnings call (next scheduled update) for a confirmation that the Cingal NDA was formally submitted and for FDA acceptance, that would finally give the stock a dated regulatory clock. Until a submission is confirmed, treat Cingal as a 2027+ US revenue story, not a near-term binary; near-term price action is being driven by the Q2 2026 earnings beat and guidance raise rather than by Cingal news.

Bull case
  • Clear regulatory route: the FDA has defined an NDA path requiring two studies including a bioequivalence study, with initiation on track for before year-end 2025 per the Nov 5, 2025 10-Q, a defined path rather than an open-ended clinical program.
  • US launch would be a new revenue stream: Anika's commercial channel is already firing, record Commercial Channel revenue of $13.9M (+17% YoY) in Q2 2026, the same sales infrastructure a Cingal US approval would plug into.
  • Wall Street is constructive on the stock: analyst consensus shows 7 of 8 ratings at Buy/Strong Buy (4 buy, 3 strong buy, 1 hold), mean price target of $21 (vs ~$19.28 current price), and B. Riley maintained Buy after the Q2 2026 beat.
Bear case
  • Timeline slippage: the NDA submission expected around Dec 31, 2025 (per the Nov 2025 10-Q) was still an open 'Cingal NDA timeline to monitor' as of the July 29, 2026 earnings report, no submission or FDA acceptance had been confirmed, and no PDUFA date exists in the data.
  • No dated catalyst: with the next hard regulatory event unscheduled, there is no binary to trade; the stock moved only +0.63% (1-day) around the expected NDA-submission date, suggesting limited near-term price sensitivity to Cingal progress.
  • FDA-timing precedent at the company: sibling product Hyalofast received an FDA deficiency letter and was removed from 2027 revenue guidance due to FDA timing uncertainty, evidence that this FDA pathway can slip.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market — MONOVISC is an approved, commercialized single-injection viscosupplement sold within Anika's Commercial Channel (no pending approval for this product).

MONOVISC sodium hyaluronate Updated Aug 1

What to watch

MONOVISC is not the near-term trade for ANIK, it is the baseline commercial cash generator, so watch quarterly "Commercial Channel" revenue and gross-margin trends as the read-through on the OA franchise. The share-price drivers to track instead are the dated catalysts on other Anika assets: the Cingal NDA submission timeline and Hyalofast PMA updates (Hyalofast was removed from 2027 revenue guidance due to FDA timing uncertainty). Note the stock is extended (+138% over 12 months, RSI-14 ~78.7, forward P/E ~47), so upside is partially priced in.

Bull case
  • MONOVISC sits in a commercial portfolio that is accelerating: Q2 2026 revenue of $32.6M (+16% YoY) beat the $29.2M consensus, GAAP EPS of $0.24 beat the $0.03 estimate, and Commercial Channel revenue hit a record $13.9M (+17% YoY), with FY2026 EBITDA-margin guidance raised to 13%-17% (from 5%-10%).
  • Anika is a focused, profitable player in early-intervention orthopedics / OA pain management (self-described 'global leader in osteoarthritis pain management'), and its hyaluronic-acid franchise benefits from an aging population needing non-surgical knee pain options.
  • Supportive tape around the name: analyst consensus is strongly buy-leaning (4 Buy + 3 Strong Buy vs 1 Hold, 0 Sell) with a mean price target of $21 (~9% above the current ~$19 price), 13F shows fresh accumulation (Assenagon +35.3%, Wealth Enhancement +55.1% in 2026-Q2), and short interest is modest at ~2.63% of estimated shares outstanding (settlement 2026-07-15, down 16% period-over-period).
Bear case
  • MONOVISC itself has no hard, dated catalyst: its regulatory binary passed long ago, and the company's actual pending decisions, Cingal's NDA (still awaiting completion of two required studies) and Hyalofast's PMA (removed from 2027 revenue guidance due to FDA timing uncertainty), are on other products, so MONOVISC cannot drive a binary move.
  • The single-injection hyaluronic-acid knee-injection market is mature, competitive and reimbursement-sensitive, with multiple rival viscosupplements; payer scrutiny of the class is a structural headwind to pricing and volume.
  • Valuation/technical stretch and balance-sheet caution: forward P/E ~47, RSI-14 ~78.7 (overbought), the stock is up 110.7% over 6 months and +138% over 12 months; operating cash flow was -$5.5M YTD and cash fell to $38.4M at June 30, 2026 from $57.5M at Dec 2025 (share repurchases + inventory build).
● neutral
Impact
PhaseNot stated
Time to marketNot applicable; this is not an Anika Therapeutics product.

HYALOMATRIX hyaluronic acid matrix Updated Nov 9

What to watch

HYALOMATRIX is not an Anika Therapeutics product. The name appears in a BusinessWire release from October 16, 2026, describing EmeraNova (BioLab Holdings) adding a "hyaluronic acid matrix technology" called Hyalomatrix for wound healing. Anika's own pipeline is focused on osteoarthritis pain management (Monovisc, Orthovisc, Cingal) and regenerative orthopedics (Integrity, Hyalofast). Investors should not confuse this wound-care technology with Anika's core business.

Bull case
  • Hyaluronic acid matrices have established clinical use in wound healing and tissue regeneration.
  • The technology was described as supporting 'tissue regeneration and complex wound healing,' addressing a real medical need.
Bear case
  • HYALOMATRIX is not an Anika Therapeutics product; it belongs to EmeraNova/BioLab Holdings, a separate private company.
  • No clinical trial data, FDA clearance status, or revenue figures for HYALOMATRIX were found in any tool result.
  • Anika's stock dropped ~25% on November 6, 2026 (closing at $14.55 from $19.33) after Q3 earnings, partly due to an FDA 'not approvable' notification for its own Hyalofast product, highlighting regulatory risk in the space.
● neutral
Impact
Phaseunknown — no Phase 2/3 or regulatory record found under this name for ANIK
Time to marketunknown — no product by this name is identifiable

INTEGRITY Updated Aug 1

What to watch

Do not trade ANIK on an "INTEGRITY" thesis, no such product could be verified despite exhaustive internal database searches; treat the name as likely a filing-metadata artifact or a red herring (all "Integrity" matches in SEC data belong to unrelated companies). If you are interested in Anika itself, the real binary items to watch are its FDA filings for Cingal (NDA) and Hyalofast (PMA), plus the next earnings print (~late October 2026) after a strong Q2 beat.

Bull case
  • Sponsor fundamentals are improving regardless of the unverifiable name: Q2 2026 revenue of $32.6M beat the $29.2M consensus and GAAP EPS of $0.24 beat the $0.03 consensus, with record commercial-channel revenue of $13.9M (+17% YoY).
  • Anika raised full-year 2026 guidance, lifting adjusted EBITDA margin guidance from 5%-10% to 13%-17%, signaling a profitability inflection for the ~$200M market-cap company.
  • Latest analyst consensus snapshot (period 2026-07-01) is bullish: 3 strong buy, 4 buy, 1 hold, 0 sell; price-target consensus mean is $21 (2 analysts) with ~8.9% implied upside vs the $18.07 reference price.
Bear case
  • The drug itself is unverifiable: no 'INTEGRITY' product, code, or brand could be found in any FDA, trial, catalyst, press, or filing dataset for ANIK, and external web verification was impossible this session, any trade thesis built on this name is unsupported.
  • Anika's actual regulatory timing is slipping: Hyalofast revenue was removed from 2027 guidance due to FDA timing uncertainty, and the Cingal NDA catalyst (dated ~2025-12-31) has no recorded outcome, meaning those binaries remain unresolved.
  • Q1 2026 GAAP EPS missed badly (-$0.37 vs -$0.21 consensus) on $4.9M of one-time severance costs, and FY2025 revenue declined 6% to $112.8M on a 17% drop in OEM channel sales.

Other drugs in filings and trials

no drug report yet
  • Hyalofast Last: BLA filed · Oct 31, 2025

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Dec 31, 2025CINGALNDA filed−2.1%0.0%
Oct 31, 2025HyalofastBLA filed+0.4%+0.7%